abstract |
The invention relates to -1 adrenergic antagonists, to -1 antagonist compositions and to a method for the < RTI ID = 0.0 > -1-adrenoreceptor antagonism, useful for the treatment of benign prostatic hyperplasia (BPH). The compound and its pharmaceutically acceptable salts have the general formula wherein W represents a bicyclic heterocyclic ring system. |